Facioscapulo-humeral dystrophy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 15: Line 15:
{{SI}}
{{SI}}


{{CMG}}; {{AE}} {{DMakkar}}


=History=
=History=
Line 41: Line 43:
**Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4).
**Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4).
**It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism.
**It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism.
**DUX4 is identified as a retrogene responsible for encoding a transcriptional regulator. Its typical expression occurs within germline cells but undergoes repression within somatic tissues.
==Pathophysiology==
==Pathophysiology==
 
Despite some remaining disagreements, there is growing consensus on a model explaining the pathophysiology of FSHD, which incorporates most of the current experimental findings.
*This model revolves around the ineffective epigenetic repression of the DUX4 retrogene located near the subtelomeric region of chromosome 4.
*Consequently, there is sporadic expression of DUX4 in the nuclei of skeletal muscle cells in individuals with FSHD.
*The genes controlled by the DUX4 transcription factor suggest various potential mechanisms of disease pathophysiology, including apoptosis, inhibition of regeneration, and an initial immune response.
'''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine
'''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine



Latest revision as of 19:09, 11 May 2024

Facioscapulo-humeral dystrophy

WikiDoc Resources for Facioscapulo-humeral dystrophy

Articles

Most recent articles on Facioscapulo-humeral dystrophy

Most cited articles on Facioscapulo-humeral dystrophy

Review articles on Facioscapulo-humeral dystrophy

Articles on Facioscapulo-humeral dystrophy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Facioscapulo-humeral dystrophy

Images of Facioscapulo-humeral dystrophy

Photos of Facioscapulo-humeral dystrophy

Podcasts & MP3s on Facioscapulo-humeral dystrophy

Videos on Facioscapulo-humeral dystrophy

Evidence Based Medicine

Cochrane Collaboration on Facioscapulo-humeral dystrophy

Bandolier on Facioscapulo-humeral dystrophy

TRIP on Facioscapulo-humeral dystrophy

Clinical Trials

Ongoing Trials on Facioscapulo-humeral dystrophy at Clinical Trials.gov

Trial results on Facioscapulo-humeral dystrophy

Clinical Trials on Facioscapulo-humeral dystrophy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Facioscapulo-humeral dystrophy

NICE Guidance on Facioscapulo-humeral dystrophy

NHS PRODIGY Guidance

FDA on Facioscapulo-humeral dystrophy

CDC on Facioscapulo-humeral dystrophy

Books

Books on Facioscapulo-humeral dystrophy

News

Facioscapulo-humeral dystrophy in the news

Be alerted to news on Facioscapulo-humeral dystrophy

News trends on Facioscapulo-humeral dystrophy

Commentary

Blogs on Facioscapulo-humeral dystrophy

Definitions

Definitions of Facioscapulo-humeral dystrophy

Patient Resources / Community

Patient resources on Facioscapulo-humeral dystrophy

Discussion groups on Facioscapulo-humeral dystrophy

Patient Handouts on Facioscapulo-humeral dystrophy

Directions to Hospitals Treating Facioscapulo-humeral dystrophy

Risk calculators and risk factors for Facioscapulo-humeral dystrophy

Healthcare Provider Resources

Symptoms of Facioscapulo-humeral dystrophy

Causes & Risk Factors for Facioscapulo-humeral dystrophy

Diagnostic studies for Facioscapulo-humeral dystrophy

Treatment of Facioscapulo-humeral dystrophy

Continuing Medical Education (CME)

CME Programs on Facioscapulo-humeral dystrophy

International

Facioscapulo-humeral dystrophy en Espanol

Facioscapulo-humeral dystrophy en Francais

Business

Facioscapulo-humeral dystrophy in the Marketplace

Patents on Facioscapulo-humeral dystrophy

Experimental / Informatics

List of terms related to Facioscapulo-humeral dystrophy


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dheeraj Makkar, M.D.[2]

History

  • The first documented case of FSHD in medical records dates back to 1852 in an autopsy report by Jean Cruveilhier.
  • In 1868, Duchenne mentioned FSHD in his important work on Duchenne muscular dystrophy.
  • FSHD was identified in 1884 by French doctors Louis Landouzy and Joseph Dejerine with their publications in 1874, 1884 and 1885.
  • In their 1886 study, Landouzy and Dejerine highlighted that FSHD runs in families, affecting four generations in one family they studied.
  • The clinical features of FSHD were officially described in 1952 after studying a large family in Utah.
  • Interest in FSHD grew from around 1980, leading to a better understanding of how the disease varies and its genetic and physiological complexities.
  • By the late 1990s, researchers began to identify the specific areas of Chromosome 4 linked to FSHD.
  • The DUX4 gene was identified in 1999, recognized for its expression and harmful effects in 2007, and in 2010, researchers unveiled the genetic process behind its expression.
  • In 2012, scientists pinpointed the gene commonly mutated in FSHD2.
  • By 2019, the initial medication aimed at combating DUX4 expression commenced clinical trials.
    • FSHD is also called:
      • Landouzy-Dejerine Disease
      • Landouzy-Dejerine syndrome
      • Erb-Landouzy-Dejerine syndrome
      • Landouzy-Dejerine dystrophy or atrophy

Classification

  • There are two genetically distinct but clinically similar forms of FSHD- FSHD1 and FSHD2.
    • Over 95% of patients have FSHD type 1 (FSHD1), which is characterized by the deletion of large repeated elements on chromosome 4q's long arm (known as the D4Z4 region).
    • A minority of patients have FSHD type 2 (FSHD2), which is caused by a mechanism independent of deletion.
    • Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4).
    • It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism.
    • DUX4 is identified as a retrogene responsible for encoding a transcriptional regulator. Its typical expression occurs within germline cells but undergoes repression within somatic tissues.

Pathophysiology

Despite some remaining disagreements, there is growing consensus on a model explaining the pathophysiology of FSHD, which incorporates most of the current experimental findings.

  • This model revolves around the ineffective epigenetic repression of the DUX4 retrogene located near the subtelomeric region of chromosome 4.
  • Consequently, there is sporadic expression of DUX4 in the nuclei of skeletal muscle cells in individuals with FSHD.
  • The genes controlled by the DUX4 transcription factor suggest various potential mechanisms of disease pathophysiology, including apoptosis, inhibition of regeneration, and an initial immune response.

Synonyms and related keywords: Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine


Facioscapulohumeral muscular dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a neuromuscular disorder.

  • Facial weakness is the initial manifestation with inability to smile, whistle, etc.
  • Shoulder muscles are weak with scapular “winging” during arm abduction.
  • Biceps / triceps are involved with sparing of the deltoids.
  • 20% progress to involve the pelvic girdle.
  • Labile hypertension, ocular involvement (Coat’s disease) and deafness can occur.

Facioscapulohumeral muscular dystrophy is usually inherited as an autosomal dominant trait. However, in up to approximately 30 percent of affected individuals, there is no apparent family history of the disorder.


Template:WikiDoc Sources